Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) EPS (Weighted Average and Diluted) (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with -$0.66 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 77.4% to -$0.66 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.33, a 103.03% increase, with the full-year FY2024 number at -$18.55, up 68.65% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.66 for Q3 2025 at 60 Degrees Pharmaceuticals, up from -$1.23 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $9.13 in Q3 2023 to a low of -$52.59 in Q4 2023.
  • A 4-year average of -$6.1 and a median of -$1.02 in 2022 define the central range for EPS (Weighted Average and Diluted).
  • Biggest YoY gain for EPS (Weighted Average and Diluted) was 8906.05% in 2023; the steepest drop was 7415.33% in 2023.
  • 60 Degrees Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.7 in 2022, then crashed by 7415.33% to -$52.59 in 2023, then soared by 110.99% to $5.78 in 2024, then crashed by 111.42% to -$0.66 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's EPS (Weighted Average and Diluted) are -$0.66 (Q3 2025), -$1.23 (Q2 2025), and -$1.56 (Q1 2025).